BACKGROUND: Testicular germ cell tumour (TGCT) patients are at increased risk of developing a contralateral testicular germ cell tumour (CTGCT). It is unclear whether TGCT treatment affects CTGCT risk. METHODS: The risk of developing a metachronous CTGCT (a CTGCT diagnosed X6 months after a primary TGCT) and its impact on patient's prognosis was assessed in a nationwide cohort comprising 3749 TGCT patients treated in the Netherlands during 1965-1995. Standardised incidence ratios (SIRs), comparing CTGCT incidence with TGCT incidence in the general population, and cumulative CTGCT incidence were estimated and CTGCT risk factors assessed, accounting for competing risks. RESULTS: Median follow-up was 18.5 years. Seventy-seven metachronous CTGCTs were diagnosed. The SIR for metachronous CTGCTs was 17.6 (95% confidence interval (95% CI) 13.9-22.0). Standardised incidence ratios remained elevated for up to 20 years, while the 20-year cumulative incidence was 2.2% (95% CI 1.8-2.8%). Platinum-based chemotherapy was associated with a lower CTGCT risk among non-seminoma patients (hazard ratio 0.37, 95% CI 0.18-0.72). The CTGCT patients had a 2.3-fold (95% CI 1.3-4.1) increased risk to develop a subsequent non-TGCT cancer and, consequently, a 1.8-fold (95% CI 1.1-2.9) higher risk of death than patients without a CTGCT. CONCLUSION: The TGCT patients remain at increased risk of a CTGCT for up to 20 years. Treatment with platinum-based chemotherapy reduces this risk.
Although most testicular germ cell tumour (TGCT) patients present with a single affected testicle, in 0.5-1% bilateral TGCT is diagnosed (Wanderås et al, 1997; Theodore et al, 2004; Fosså et al, 2005; Hentrich et al, 2005) . Testicular germ cell tumour patients remain at increased risk of developing a contralateral testicular germ cell tumour (CTGCT) during follow-up (Osterlind et al, 1991; van Leeuwen et al, 1993; Wanderås et al, 1997; Fosså et al, 2005; Andreassen et al, 2011) . It remains unclear whether primary treatment, especially platinum-based chemotherapy, affects the risk of developing a metachronous CTGCT. In a previous report from our institute we found a strongly increased CTGCT risk compared with the general population after surgery or radiotherapy but not after chemotherapy (van Leeuwen et al, 1993) . Several other studies reported a higher CTGCT risk for seminoma compared with non-seminoma TGCT patients, which may reflect differences in treatment (Che et al, 2002; Theodore et al, 2004; Fosså et al, 2005) . However, few studies directly evaluated the effect of TGCT treatment on CTGCT risk, with controversial results (van Basten et al, 1997; Wanderås et al, 1997) .
This study assesses long-term CTGCT risk, risk factors for developing a CTGCT and the impact of a CTGCT and its treatment on patient prognosis in a large nationwide cohort of TGCT patients treated in the Netherlands between 1965 and 1995.
PATIENTS AND METHODS
Patient selection and data collection have been described in detail in earlier reports (van Leeuwen et al, 1993; van den Belt-Dusebout et al, 2007) . Briefly, TGCT patients were identified through the former Netherlands Committee on Testicular Tumors registry *Correspondence: Dr FE van Leeuwen; E-mail: f.v.leeuwen@nki.nl Presented at the joint ECCO 15 -34th ESMO Multidisciplinary Congress and the 7th Copenhagen workshop on CIS testis and germ cell cancer. (Zwaveling and Soebhag, 1985) and tumour registries at several referral hospitals (Netherlands Cancer Institute, Daniel den Hoed Cancer Center, University Medical Center Groningen and Amsterdam Medical Center). For this study, an additional 357 patients treated at the Radboud University Medical Center in 1982-1995 were also included.
Data were collected on dates of birth and tumour diagnoses, histology, primary and relapse treatment (radiation fields and chemotherapy regimens), date and cause of death. Medical followup regarding TGCT treatment and second malignancies (SMNs) was obtained actively from medical charts, general practitioners and attending physicians, and was complete until at least 1 January 2000, the date of death, or the date of emigration for 90% of all patients (van den Belt-Dusebout et al, 2007) . Subsequently, we retrieved data on SMNs, including CTGCTs, diagnosed in the period 1989-2007 from the Netherlands Cancer Registry and dates of death or emigration up to January 2008 from the Dutch Central Bureau for Genealogy and the Dutch municipal administrations.
Treatment
Changes in TGCT treatment after orchiectomy were described in detail previously (van Leeuwen et al, 1993; van den Belt-Dusebout et al, 2007) . Briefly, stage I and II seminoma and non-seminoma patients received radiotherapy to the para-aortic and ipsilateral iliacal nodes (30-35 and 40-50 Gy in fractions of 2 Gy, respectively). Since the mid-1980s, radiotherapy dose has been reduced to 26 Gy for seminoma while surveillance became common for stage I non-seminomas. Until the late 1970s treatment for disseminated non-seminomas generally consisted of dactinomycin alone or combined with vincristine, vinblastine or bleomycin. Both disseminated seminomas and non-seminomas were treated primarily with cisplatin, vinblastine and bleomycin (PVB) since 1977 and with bleomycin, etoposide and cisplatin (BEP) from the mid-1980s. Besides PVB and BEP several other regimens have been used, mainly within randomised trials. For this study all chemotherapy regimens with cis-or carboplatin were categorised as 'Platinum-based' while all other regimens were grouped under 'Other'.
Statistical analysis
As most relapses occurred early, relapse treatment before a CTGCT was combined with primary treatment. We compared CTGCT incidence with age-and calendar year-specific TGCT incidence rates for the Dutch population, accounting for person-years of observation. Cancer incidence data from the Eindhoven Cancer Registry for [1970] [1971] [1972] [1973] [1974] [1975] [1976] [1977] [1978] [1979] [1980] [1981] [1982] [1983] [1984] [1985] [1986] [1987] [1988] and from the NCR for 1989-2009 were used as reference rates (The Netherlands Cancer Registry: Cancer in figures, 2012).
Standardised incidence ratios (SIR) were calculated as observed over expected number of CTGCTs and absolute excess risks (AER) as the observed minus the expected CTGCT number, divided by person-years at risk, times 10 000. Only metachronous CTGCTs, defined as any CTGCT diagnosed X6 months after the primary TGCT, were analysed. Time at risk therefore started 6 months after TGCT diagnosis and ended at date of CTGCT diagnosis, emigration, death or most recent medical information. Tests for association and linear trend for both SIR and AER were based on Poisson regression models (Breslow and Day, 1987; Boshuizen and Feskens, 2010) . Cumulative CTGCT incidence and confidence intervals were estimated in the presence of death as competing risk (Gooley et al, 1999; Choudhury 2002) .
Effects of TGCT treatment on metachronous CTGCT risk were quantified using multivariable regression with death as competing risk (Fine and Gray, 1999) . To compare the risk of subsequent non-TGCT cancer with and without a prior CTGCT we used a competing risk regression model (death as competing risk) with CTGCT as a time-dependent covariate, allocating follow-up time to the 'no CTGCT' group until metachronous CTGCT occurrence. The model also included age at primary TGCT diagnosis and receipt of radiotherapy and chemotherapy for the primary TGCT (or for any recurrence of this cancer before the CTGCT diagnosis). Similarly, we used a Cox model with CTGCT as a time-dependent covariate, to compare survival with and without a CTGCT. This model used attained age as time-scale and also adjusted for age at diagnosis and histology of the primary TGCT, period of treatment and receipt of radiotherapy and chemotherapy for the primary TGCT (or radiotherapy or chemotherapy for any recurrence of this cancer before the CTGCT diagnosis). Three patients with a CTGCT had an invasive non-testis cancer (two stomach cancers and one lung cancer) before the development of their CTGCT, whereas another 396 had an invasive non-testis cancer other than nonmelanoma skin cancer but no CTGCT. The three patients with a second cancer before their CTGCT were not censored in the analysis of CTGCT risk factors, but were censored in the analysis of survival after a CTGCT and in the analysis of the impact of developing a CTGCT on the risk of an invasive non-testis cancer and the risk of death after a primary TGCT, where the CTGCT was treated as a time-dependent event.
Analyses were performed using STATA statistical software (Stata 11, StataCorp. LP, College Station, TX, USA) and a P-value o0.05 was considered statistically significant.
RESULTS
The cohort comprised 1716 (45.8%) seminoma and 2033 (54.2%) non-seminoma TGCT patients (Table 1 ). The majority of seminoma patients (86.9%) received radiotherapy, whereas most non-seminoma patients either received chemotherapy (61.8%) or surgery alone (24.4%). The median follow-up was 18.5 years; 23.7% of the survivors accumulated X25 follow-up years.
Eighty-seven patients, 48 with a primary seminoma and 39 with a non-seminoma TGCT, developed a CTGCT. Ten CTGCTs were diagnosed within 6 months of the primary TGCT (synchronous CTGCT), nine among seminoma (seven of which were also of the seminoma subtype) and one (a seminoma) among non-seminoma patients.
The remaining 77 CTGCTs were diagnosed X6 months after the primary TGCT. The median interval until diagnosis of these metachronous CTGCT did not differ between seminoma and nonseminoma patients (8.5 years, range 0.8-23.9 years) and 63.6% occurred within 10 years of the primary TGCT. Only two metachronous CTGCT were diagnosed after 420 year. Three metachronous CTGCT patients also experienced a relapse, which preceded the CTGCT in all cases. Irrespective of TGCT histology, metachronous CTGCTs were more frequently of the seminoma than of the non-seminoma subtype; 32 (82%) CTGCTs among seminoma and 23 (61%) CTGCTs among non-seminoma patients were seminomas.
Relative risk compared with the general population
Overall, the incidence of metachronous CTGCT in our cohort was 17.6 (95% CI 13.9-22.0) times higher than the expected TGCT incidence based on general population rates ( Table 2 ). The SIRs did not vary by age at TGCT diagnosis (P heterogeneity ¼ 0.19) or follow-up duration (P trend ¼ 0.13, restricted to the first 25 years of follow-up). The SIR was lower for patients diagnosed in the period 1976-1985 and 1986-1995 compared with patients diagnosed during 1965-1975 (1976-1985 vs 1965-1975 : relative risk (RR) 0.38, P ¼ 0. 001; 1986 -1995 vs 1965 -1975 .
The SIR was 24.9 after a seminoma and 13.6 after a nonseminoma TGCT (seminoma vs non-seminoma: RR 1.84, P ¼ 0.008). The SIR was significantly lower for non-seminoma patients treated with chemotherapy (SIR 7.6, 95% CI 4.3-12.6) compared with patients treated without chemotherapy (chemotherapy vs no chemotherapy: RR 0.30, Po0.001). This association remained after adjusting for period of diagnosis and follow-up interval (chemotherapy vs no chemotherapy: RR 0.34, Po0.001, data not shown). For non-seminoma patients who received chemotherapy the median time until metachronous CTGCT was 9.1 years compared with 8.2 years for those treated without chemotherapy (P ¼ 0.45).
Absolute excess risk compared with the general population
We observed 11.4 excess CTGCTs (95% CI 8.9-14.4) for every 1000 patients followed for 10 years ( Table 2 ). The AER decreased with age for seminoma (P trend ¼ 0.015) and, nonsignificantly, for nonseminoma patients (P trend ¼ 0.067), but the number of events in the age category X40 years was very small among the nonseminoma patients. The AER did not vary by treatment period for either seminoma or non-seminoma. The AER did vary with primary treatment among non-seminoma patients (P heterogeneity o0.001), with a lower AER for patients treated with chemotherapy (AER 5.8, 95% CI 2.9-10.2) compared with patients treated without chemotherapy (AER chemotherapy vs no chemotherapy: P ¼ 0.001).
Cumulative incidence
The cumulative incidence of metachronous CTGCT was 1.4% (95% CI 1.0-1.8%) after 10 years and 2.2% (95% CI 1.8-2.8%) after 20 years of follow-up (Table 2 ). Cumulative incidence increased at a fairly constant rate during the follow-up and reached a plateau after 20 years of follow-up; no CTGCT was diagnosed after the 24th year of follow-up.
Among seminoma patients, only age at diagnosis was found to be associated with CTGCT cumulative incidence. At 20 years of follow-up, seminoma patients o30 years had a cumulative incidence of 4.3% (95% CI 2.4-7.0%), but incidence decreased for patients who were older at TGCT diagnosis (hazard ratio (HR) per 10-year increase: 0.47, 95% CI 0.26-0.84, data not shown). Figure 1 shows the cumulative incidence by attained age according to age at diagnosis (o30 years vs X30 years) for seminoma patients. The CTGCT incidence increased much more rapid by attained age for younger patients (HR 0.30 for X30 years vs o30 years, Po0.001).
Chemotherapy for non-seminoma TGCT was associated with a significantly lower cumulative CTGCT incidence (Figure 2) . However, although receipt of chemotherapy was associated with a 43-fold reduction in cumulative CTGCT incidence (HR 0.28 for chemotherapy vs no chemotherapy, Po0.001) among patients o30 years, the reduction appeared slightly more limited for patients X30 years at diagnosis (chemotherapy vs no chemotherapy: HR 0.42, P ¼ 0.16). In multivariable analysis, period of diagnosis did not affect CTGCT risk, whereas older age at diagnosis was associated with a slightly lower CTGCT risk. Platinum-based chemotherapy was associated with a lower CTGCT risk among non-seminoma patients (HR 0.37, 95% CI 0.19-0.77; Table 3 ). Although only based on two CTGCT, non-platinum regimens appeared also associated with lower CTGCT risk.
Association of metachronous CTGCT with survival
The 5-and 10-year overall survival rates after metachronous CTGCT diagnosis for the 74 patients without a prior non-testis second cancer were 93.0% (95% CI 84.3-97.1) and 86.1% (95% CI 74.7-92.6), respectively. Median age at time of death for deceased patients was 49.7 years (range 33-67 years). Only 2 of these 74 CTGCT patients died directly due to disseminated testicular cancer, whereas 9 other CTGCT patients died due to a non-testis second cancer (Supplementary Table S1 ). Thirteen of these CTGCT patients (22.1%) had at least one other non-TGCT secondary cancer after their primary TGCT. Patients with a metachronous CTGCT had a 2.3 times (95% CI 1.3-4.1, P ¼ 0.006) higher risk of developing a subsequent non-TGCT invasive cancer (adjusted for age, chemotherapy and radiotherapy for primary TGCT; data not shown). On the basis of 16 deaths among the 74 CTGCT patients without a prior non-testis second cancer, patients with a CTGCT also had a 1.8 times higher risk (95% CI 1.1-2.9, P ¼ 0.026; data not shown) of death than patients who did not develop a CTGCT.
DISCUSSION
In this large cohort study TGCT patients had an almost 18-fold increased risk to develop a metachronous CTGCT compared with the Dutch male population. When considering that TGCTsurvivors have only one testicle at risk for CTGCTs, while the reference rates for the general population concern cancer in any of two testes, the risk expressed in testis-years could even be twice as high. The 20-year cumulative CTGCT incidence reached 2.2%, indicating that conditional on surviving, about one in every 45 TGCT patients will develop a CTGCT within 20 years of their primary TGCT. Non-seminoma TGCT treatment with platinumbased chemotherapy was associated with a lower CTGCT risk. A CTGCT diagnosis was associated with worse prognosis, mostly due to deaths from subsequent non-TGCT malignancies.
This study is to our knowledge the largest cohort study on CTGCT risk with complete treatment data and complete follow-up All treatment administered after surgery (orchiectomy with or without retroperitoneal lymph node dissection), including treatment for relapse/recurrence before metachronous CTGCT diagnosis.
Risk of contralateral testicular cancer M Schaapveld et al
for CTGCT. Our analysis of CTGCT risk was based on all treatment received before CTGCT diagnosis, which allows reliable assessment of the effect of treatment on CTGCT risk. In studies based on data from population-based cancer registries, treatment misclassification is a common problem, either due to underreporting of chemotherapy in initial treatment or due to omission of salvage Abbreviations: AER ¼ absolute excess risk; 95% CI ¼ 95% confidence interval; CTGCT ¼ contralateral testicular germ cell tumour; CT ¼ chemotherapy; SIR ¼ standardised incidence ratio; TGCT ¼ testicular germ cell tumour.
a Includes three patients, two seminoma and one non-seminoma, with a non-testis second cancer (two stomach cancers, treated with surgery only, and one lung cancer) before the CTGCT diagnosis. Person-time in follow-up interval X25 years: 2305 for seminoma and 2123 years for non-seminoma (4428 for combined group). f Two patients with 2xBEP (Bleomycin, Etoposide, Cisplatin), one patient with 3xBEP þ 1xEP (Etoposide, Cisplatin), four patients with 4xBEP, one patient with 4xEP, one patient with 4xCEB (Carboplatin, Etoposide, Bleomycin), one patient with 4xVIP (Etoposide, Ifosfamide, Cisplatin), three patients with 4xPVB (Cisplatin, Vinblastin, Bleomycin). treatment, thus limiting conclusions regarding the association of TGCT treatment with CTGCT risk (Osterlind et al, 1991; Fosså et al, 2005; Andreassen et al, 2011) .
Testicular intraepithelial neoplasms (TINs) are considered precursor lesions for seminoma and non-seminoma TGCT. In a Danish study, contralateral testicle biopsies of 500 TGCT patients revealed contralateral TIN lesions in 5.4% (von der Maase et al, 1986) . Fifty percent of the patients with a TIN lesion, who did not receive chemotherapy, developed an invasive TGCT within 5 years, whereas none of the patients who received platinum-based chemotherapy did so, suggesting that platinum-based chemotherapy eradicated TIN lesions. Nonetheless, Greist et al (1984) found residual carcinoma in the removed testes of 3 out of 20 patients who underwent orchiectomy after platinum-based chemotherapy for disseminated TGCT. Recently, Kleinschmidt et al (2009) reported persistent TIN after rebiopsy among 5 out of 11 patients with a primary TIN who had received platinum-based chemotherapy, 2 of whom later developed an invasive TGCT. The Danish group also showed that among 33 patients with disseminated TGCT and a contralateral TIN lesion, all treated with chemotherapy (BEP 26, PVB 6, other 1), 4 patients still developed a CTGCT (Christensen et al, 1998) . Other studies also reported CTGCT among patients treated with cisplatinum-containing chemotherapy (Wanderås et al, 1997; Theodore et al, 2004; Hentrich et al, 2005; van den Belt-Dusebout et al, 2007) . In our study, 12 of the 77 metachronous CTGCT were diagnosed in non-seminoma patients Age.30 Figure 1 Cumulative incidence with 95% CIs of metachronous CTGCTs for patients with a seminoma TGCT by attained age, according to age at diagnosis (o30 vs X30 years). Non-seminoma TGCT, age at dx .30 years Figure 2 Cumulative incidence with 95% CIs of CTGCTs for patients with a non-seminoma TGCT by attained age, according to treatment with and without chemotherapy and age at diagnosis (A: o30 years; B: X30 years). Risk of contralateral testicular cancer M Schaapveld et al treated with platinum-based chemotherapy (PVB 3 patients, BEP 7 patients, EP 1 patient, VIP 1 patient, CEB 1 patient). Therefore, it appears that platinum-based chemotherapy does not completely block the development of CTGCT. Our study does not lend support to delayed CTGCT development after platinum-based chemotherapy, as postulated by Christensen et al (1998) . With a median follow-up of 18.5 years we found no difference in the distribution of CTGCT by follow-up time between non-seminoma patients treated with or without chemotherapy (9.1 vs 8.2 years). The occurrence of metachronous CTGCTs after 410 years of follow-up (36% of CTGCTs in our cohort) proved to be no rare event. Similarly, a study among Norwegian males treated at the Radium Hospital reported that 17% of all CTGCTs were diagnosed after X10 years, whereas in a US study 30% of all CTGCTs were diagnosed after X10 years of follow-up (Wanderås et al, 1997; Che et al, 2002) . Assuming that all CTGCTs derive from a pre-existing TIN, that the prevalence of TIN is 5% (based on biopsy studies) and that our estimate of the 10-year cumulative incidence (2.2%) is correct, we would expect that the risk of progression to invasive cancer within 5 years would be o50% currently reported (von der Maase et al, 1986; Dieckmann et al, 2007) .
Incidence patterns for metachronous CTGCTs by age group appear to mimic incidence patterns of de novo TGCTs. Although the SIR for CTGCT did not differ by age at TGCT diagnosis, the cumulative incidence decreased with older age at TGCT diagnosis. Although a decreasing CTGCT risk with older age at primary TGCT diagnosis has been observed in several other studies (Wanderås et al, 1997; Theodore et al, 2004; Fosså et al, 2005) , no good explanation for this finding has been given. One could speculate that patients who develop testicular cancer later in life are less likely to harbour premalignant cells in the contralateral testis or that a lower fraction of contralateral TIN lesions transforms into invasive tumour among older patients.
The occurrence of a CTGCT appeared to affect patient's prognosis in our cohort. This may partly reflect the impact of additional CTGCT treatment on late treatment complications, especially non-testis second cancers, as suggested by the two-fold risk increase for a non-testis second cancer among patients with a CTGCT compared with patients without a CTGCT in our study.
In contrast with our results, Fosså et al (2005) previously found no indication that prognosis for a TGCT patient was compromised by the diagnosis of a metachronous CTGCT and even found a slightly lower risk of death for patients with a CTGCT (HR 0.76; 95% CI 0.45-1.26). The cohort studied by Fosså et al was diagnosed in a more recent time period; 86% of all included patients in their study were diagnosed with a primary TGCT since 1983. In our cohort 49% of all patients were diagnosed before 1983, in a period in which higher radiation doses and more extensive radiation fields were used.
A potential weakness of our study is that we did not collect information on a history of testicular maldescent, testicular trauma, infertility, testicular atrophy or removal of a testis due to trauma or maldescent. Although these factors could be associated with the risk of developing a CTGCT, they are unlikely to be associated with treatment for the primary testicular cancer and will therefore not confound the reduced risk estimate of CTGCT, which we observed among patients treated with (platinum-based) chemotherapy.
Clinicians can use the results of our study to inform and reassure patients under long-term follow-up about their very low remaining risk to develop a CTGCT. In addition, patients treated with chemotherapy can be informed that albeit they have a very low risk to develop a CTGCT, the risk is not absent. On the basis of our results clinicians should be aware that especially young seminoma patients and young non-seminoma patients, not treated with chemotherapy, have a relatively high risk to develop a CTGCT, reaching about 4%, 20 years after the primary TGCT.
Conclusions
Treatment of non-seminoma TGCT with platinum-based chemotherapy is associated with a markedly lower CTGCT risk. The CTGCT risk remains elevated for at least 20 years, at which time the cumulative incidence reaches 2.2%.
